The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …

Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …

Introduction To evaluate the efficacy and safety of osimertinib plus bevacizumab for
previously untreated patients with advanced nonsquamous NSCLC harboring EGFR …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC …

Introduction Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …

Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated
EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study …

Background This multicenter phase 2 trial evaluated the safety and efficacy of osimertinib
and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR …